Sign in

NCT07752940Not yet recruiting

Smartphone Based-PPG Assessment of REconversion in Persistent Atrial Fibrillation

Smartphone Based-PPG Assessment of REconversion in Persistent Atrial Fibrillation: a Randomized Controlled Trial

Source: ClinicalTrials.gov · Last updated 7 Aug 2026

Brief summary (registry, in English)

This study investigates whether a smartphone application that measures heart rhythm using light, a technique known as photoplethysmography or PPG, can accurately detect when the cardiac arrhythmia atrial fibrillation (AF) spontaneously terminates and the heart returns to normal sinus rhythm. This is a prospective, multicentre randomised controlled study conducted at Hospital East Limburg and University Hospitals Leuven. Continuous heart rhythm monitoring with conventional equipment is often not feasible in the home setting because of the high cost and complexity of the equipment. Smartphone-based PPG monitoring offers a practical and affordable alternative. The study will include 200 adult patients with known AF who are scheduled for elective electrical cardioversion. Patient will be randomised to either standard of care (no remote monitoring) or smartphone-based PPG monitoring. During the seven days preceding the procedure, participants in the intervention group will perform PPG and ECG measurements at predefined times using their smartphone and a chest strap. The primary objective is to determine whether this intermittent, app-guided monitoring can detect spontaneous conversion to normal sinus rhythm before the planned cardioversion, thereby preventing unnecessary hospital admissions. In addition, we will evaluate the relationship between symptoms and cardiac rhythm, adherence to and user experience with self-monitoring, and the predictive value of the measured parameters for recurrence of AF or atrial flutter during one year of follow-up.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
200 (estimated)
First submitted
23 Jul 2026
Start date
1 Aug 2026
Primary completion date
Jul 2027
Lead sponsor
Ziekenhuis Oost-Limburg
NCT number
NCT07752940

What you commit to

  • Study type: Interventional
  • Planned participants: 200
  • From 1 Aug 2026 to the primary completion date, Jul 2027
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Cardiac implantable devices such as pacemakers, CRT's or ICD's.

Other

  • No access to a smartphone or unable to perform PPG measurements independently.
  • Active follow-up in Fibricheck care pathways

Who the study is looking for

  • Provide signed and dated informed consent
  • Males or females aged ≥ 18 years
  • Diagnosis of atrial fibrillation based on ECG in medical history
  • Patient in atrial fibrillation when planned for electrical cardioversion as evidenced by an ECG
  • In possession of a smartphone
  • Being able and having the time to perform heart rhythm measurement using the FibriCheck application at home

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Ziekenhuis Oost-Limburg
Coordinator of this site? Confirm its status
GenkBelgiumUnknown status
University Hospitals Leuven
Coordinator of this site? Confirm its status
LeuvenBelgiumUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.